id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-332788-8lq9qygn	Manda, Sudhir	Feasibility of Long-Term Proteasome Inhibition in Multiple Myeloma by In-Class Transition from Bortezomib to Ixazomib	2020-07-06		.txt	text/plain	4412	223	51	BACKGROUND: The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral ixazomib-lenalidomide-dexamethasone (ixazomib-Rd) with the aim of increasing proteasome inhibitor (PI)-based treatment adherence/duration while maintaining quality of life (QoL) and improving outcomes. 19, 20, 25 The US MM-6 study is investigating the novel iCT approach with the aim of increasing PI-based treatment duration and adherence, maintaining HRQoL, and improving outcomes in NDMM patients, with a study design that allows centers to follow their standard-of-care procedures for first-line bortezomib-based induction therapy. In this context, and with enrollment and follow-up ongoing, we demonstrate that iCT from parenteral bortezomib-based induction to all-oral ixazomib-Rd is feasible, allowing long-term PI-based treatment that is well tolerated with promising efficacy, good medication adherence and no adverse impact on patients' • The US MM-6 study was therefore designed to evaluate a novel iCT approach in the community-based setting with the aims of increasing PI-based treatment duration and adherence, maintaining HRQoL, and improving outcomes in a representative, real-world, community population of NDMM patients.	./cache/cord-332788-8lq9qygn.txt	./txt/cord-332788-8lq9qygn.txt